Cassava Sciences, Inc. (SAVA)
- Previous Close
1.6000 - Open
1.5800 - Bid 1.4600 x 200
- Ask 1.5500 x 200
- Day's Range
1.4500 - 1.5800 - 52 Week Range
1.1500 - 42.2000 - Volume
670,024 - Avg. Volume
1,583,488 - Market Cap (intraday)
77.293M - Beta (5Y Monthly) -2.32
- PE Ratio (TTM)
-- - EPS (TTM)
-1.3800 - Earnings Date May 8, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Dec 13, 2012
- 1y Target Est
2.00
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. Cassava Sciences, Inc. was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.
www.cassavasciences.comRecent News: SAVA
View More
Performance Overview: SAVA
Trailing total returns as of 5/6/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SAVA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SAVA
View MoreValuation Measures
Market Cap
72.94M
Enterprise Value
-48.19M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.50
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-57.18%
Return on Equity (ttm)
-17.19%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-24.34M
Diluted EPS (ttm)
-1.3800
Balance Sheet and Cash Flow
Total Cash (mrq)
128.57M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-72.99M